Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)
Latest Information Update: 28 Jan 2020
At a glance
- Drugs Presatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Challenge
- Sponsors Gilead Sciences
- 23 Jan 2020 Results identifing and characterizing presatovir treatment-emergent amino acid substitutions in F protein, and assess their effects on in vitro susceptibility to presatovir, viral fitness in cell-based virus replication assays, and clinical outcomepublished in the Journal of Infectious Diseases
- 07 Sep 2014 Results of exposure-antiviral activity relationship analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 26 Jul 2014 Primary endpoint has been met. (Viral load AUC after initial dose)